Radiotherapy in Locoregional Recurrent Breast Carcinoma.
- Author:
Sung Whan HA
1
;
Mi Gyoung YANG
;
Woong Ki CHUNG
;
Charn Il PARK
;
Yung Jue BANG
;
Noe Kyung KIM
;
Kuk Jin CHOE
Author Information
1. Department of Therapeutic Radiology, College of Medicine, Seoul National University, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Radiotherapy;
Breast cancer;
Recurrent
- MeSH:
Breast Neoplasms*;
Breast*;
Female;
Follow-Up Studies;
Hand;
Humans;
Lymph Nodes;
Neoplasm Metastasis;
Radiotherapy*;
Recurrence;
Survivors;
Thoracic Wall
- From:Journal of the Korean Society for Therapeutic Radiology
1988;6(2):203-210
- CountryRepublic of Korea
- Language:English
-
Abstract:
Thirty eight women with recurrent breast carcinoma involving chest wall and/or regional lymph nodes after surgery with or without systemic therapy were treated with radiation between 1979 and 1986. Among them, 5 patients were excluded from analysis because of incomplete treatment. The median follow up of survivors was 30 months (randged 1-79 months). Fifteen (45%) patients had their disease confined to the chest wall and eighteen patients had lymph node involvement as some of their locoregional recurrent disease. Within 36 months after the initial treatment, 87% of recurrences manifested themselves. All patients had radiotherapy to at least the site of involvement. In 8 patients, recurrent tumors were treated with complete excision followed by radiation. Of the remaining 25 patients, 18(72%) had complete response (CR) following radiotherapy. The actuarial 3-year survival of all patients following locoregional recurrence was 50%. Three year survival was 24% in those 25 patients who had recurrences within 24 months of the initial treatment. For those 8 patients whose recurrences occurred after more than 24 month disease free interval, the 3-year survival was 100%. For those patients with recurrences confined to chest wall alone, 3-year survival was 57%. The patients who had lymph node involvement as part of their locoregional recurrences had a 43% 3-year survival. The majority of them developed distant metastases. Those patients who had a CR showed 63% 3-year survival. On the other hand, 1 year survival was only 33% for those patients who had a less than CR. Three patients developed carcinoma of the contralateral breast following radiotherapy. Three year survival following locoregional recurrence was 40% for patients whose initial treatment for their primary breast carcinoma was surgery and adjuvant systemic therapy. For those patients whose primary breast carcinoma was treated by surgery alone, the 3-year survival following locoregional recurrence was 71%. In patients who had subsequent recurrence after radiotherapy, the actuarial survival was 25% at 2 years.
